Diabetic Neuropathic Pain - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Neuropathic Pain - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Neuropathic Pain - Pipeline Review, H1 2015', provides an overview of the Diabetic Neuropathic Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Neuropathic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathic Pain Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathic Pain - Overview 10
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11
Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Neuropathic Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diabetic Neuropathic Pain - Products under Development by Companies 19
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 21
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 22
Acorda Therapeutics, Inc. 22
Astellas Pharma Inc. 23
AstraZeneca PLC 24
BioDelivery Sciences International, Inc. 25
Daiichi Sankyo Company, Limited 26
Dong-A Socio Group 27
Eli Lilly and Company 28
Glenmark Pharmaceuticals Ltd. 29
Immune Pharmaceuticals, Ltd. 30
KunWha Pharmaceutical Co., Ltd. 31
Kyorin Pharmaceutical Co., Ltd. 32
Laboratorios Del Dr. Esteve S.A. 33
Lohocla Research Corporation 34
Mertiva AB 35
Pharmaleads 36
RAPID Pharmaceuticals AG 37
Relmada Therapeutics, Inc. 38
SK Biopharmaceuticals Co., Ltd. 39
Sphaera Pharma Pvt. Ltd. 40
Diabetic Neuropathic Pain - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
(amitriptyline + ketamine hydrochloride) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AS-1069562 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AZD-5213 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
capsaicin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
clonidine hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
d-Methadone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DA-3030 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
duloxetine hydrochloride DR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
E-52862 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GERP-001 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GRC-17536 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ibudilast - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Kindolor - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
mepivacaine hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
mirogabalin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NG2-GAD - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PGN-305 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PL-37 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pregabalin ER - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PRTT-200 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RAP-103 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SKL-NP - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SPC-612 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Diabetic Neuropathic Pain - Recent Pipeline Updates 85
Diabetic Neuropathic Pain - Dormant Projects 97
Diabetic Neuropathic Pain - Discontinued Products 100
Diabetic Neuropathic Pain - Product Development Milestones 102
Featured News & Press Releases 102
Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 102
Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 102
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 103
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 103
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 104
Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Diabetic Neuropathic Pain, H1 2015 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Diabetic Neuropathic Pain - Pipeline by Acorda Therapeutics, Inc., H1 2015 22
Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H1 2015 23
Diabetic Neuropathic Pain - Pipeline by AstraZeneca PLC, H1 2015 24
Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2015 25
Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 26
Diabetic Neuropathic Pain - Pipeline by Dong-A Socio Group, H1 2015 27
Diabetic Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2015 28
Diabetic Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 29
Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 30
Diabetic Neuropathic Pain - Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2015 31
Diabetic Neuropathic Pain - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 32
Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 33
Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H1 2015 34
Diabetic Neuropathic Pain - Pipeline by Mertiva AB, H1 2015 35
Diabetic Neuropathic Pain - Pipeline by Pharmaleads , H1 2015 36
Diabetic Neuropathic Pain - Pipeline by RAPID Pharmaceuticals AG, H1 2015 37
Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2015 38
Diabetic Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 39
Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015 40
Assessment by Monotherapy Products, H1 2015 41
Assessment by Combination Products, H1 2015 42
Number of Products by Stage and Target, H1 2015 44
Number of Products by Stage and Mechanism of Action, H1 2015 46
Number of Products by Stage and Route of Administration, H1 2015 48
Number of Products by Stage and Molecule Type, H1 2015 50
Diabetic Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2015 85
Diabetic Neuropathic Pain - Dormant Projects, H1 2015 97
Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H1 2015 98
Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H1 2015 99
Diabetic Neuropathic Pain - Discontinued Products, H1 2015 100
Diabetic Neuropathic Pain - Discontinued Products (Contd..1), H1 2015 101